vs
Side-by-side financial comparison of Celldex Therapeutics, Inc. (CLDX) and Lantheus Holdings, Inc. (LNTH). Click either name above to swap in a different company.
Lantheus Holdings, Inc. is the larger business by last-quarter revenue ($406.8M vs $120.0K, roughly 3389.9× Celldex Therapeutics, Inc.). Lantheus Holdings, Inc. runs the higher net margin — 13.3% vs -67764.2%, a 67777.5% gap on every dollar of revenue. On growth, Lantheus Holdings, Inc. posted the faster year-over-year revenue change (4.0% vs -89.8%). Lantheus Holdings, Inc. produced more free cash flow last quarter ($81.4M vs $-65.2M). Over the past eight quarters, Lantheus Holdings, Inc.'s revenue compounded faster (4.9% CAGR vs -12.3%).
Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops targeted immunotherapies for hard-to-treat cancers and rare immunological diseases. Its pipeline covers antibody-drug conjugates, monoclonal antibodies and other novel therapies, serving patients with high unmet medical needs mainly across North America and Europe.
Lantheus Holdings, Inc. is a global healthcare firm specializing in the development, manufacturing and commercialization of innovative diagnostic imaging agents and related solutions. Its offerings cover core medical segments including oncology, cardiology and urology, with primary markets across North America and other key global regions.
CLDX vs LNTH — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $120.0K | $406.8M |
| Net Profit | $-81.3M | $54.1M |
| Gross Margin | — | 59.2% |
| Operating Margin | -72628.3% | 19.0% |
| Net Margin | -67764.2% | 13.3% |
| Revenue YoY | -89.8% | 4.0% |
| Net Profit YoY | -72.7% | 558.8% |
| EPS (diluted) | $-1.23 | $0.86 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $120.0K | $406.8M | ||
| Q3 25 | $0 | $384.0M | ||
| Q2 25 | $730.0K | $378.0M | ||
| Q1 25 | $695.0K | $372.8M | ||
| Q4 24 | $1.2M | $391.1M | ||
| Q3 24 | $3.2M | $378.7M | ||
| Q2 24 | $2.5M | $394.1M | ||
| Q1 24 | $156.0K | $370.0M |
| Q4 25 | $-81.3M | $54.1M | ||
| Q3 25 | $-67.0M | $27.8M | ||
| Q2 25 | $-56.6M | $78.8M | ||
| Q1 25 | $-53.8M | $72.9M | ||
| Q4 24 | $-47.1M | $-11.8M | ||
| Q3 24 | $-42.1M | $131.1M | ||
| Q2 24 | $-35.8M | $62.1M | ||
| Q1 24 | $-32.8M | $131.1M |
| Q4 25 | — | 59.2% | ||
| Q3 25 | — | 57.9% | ||
| Q2 25 | — | 63.8% | ||
| Q1 25 | — | 63.8% | ||
| Q4 24 | — | 63.5% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 65.4% |
| Q4 25 | -72628.3% | 19.0% | ||
| Q3 25 | — | 11.4% | ||
| Q2 25 | -8747.5% | 23.3% | ||
| Q1 25 | -9027.2% | 27.4% | ||
| Q4 24 | -4768.3% | 29.1% | ||
| Q3 24 | -1633.5% | 35.3% | ||
| Q2 24 | -1854.2% | 26.1% | ||
| Q1 24 | -26030.8% | 28.8% |
| Q4 25 | -67764.2% | 13.3% | ||
| Q3 25 | — | 7.2% | ||
| Q2 25 | -7753.4% | 20.8% | ||
| Q1 25 | -7740.4% | 19.6% | ||
| Q4 24 | -4007.8% | -3.0% | ||
| Q3 24 | -1320.0% | 34.6% | ||
| Q2 24 | -1434.8% | 15.8% | ||
| Q1 24 | -21030.8% | 35.4% |
| Q4 25 | $-1.23 | $0.86 | ||
| Q3 25 | $-1.01 | $0.41 | ||
| Q2 25 | $-0.85 | $1.12 | ||
| Q1 25 | $-0.81 | $1.02 | ||
| Q4 24 | $-0.71 | $-0.18 | ||
| Q3 24 | $-0.64 | $1.79 | ||
| Q2 24 | $-0.54 | $0.88 | ||
| Q1 24 | $-0.56 | $1.87 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $518.6M | $359.1M |
| Total DebtLower is stronger | — | $568.7M |
| Stockholders' EquityBook value | $527.2M | $1.1B |
| Total Assets | $583.0M | $2.2B |
| Debt / EquityLower = less leverage | — | 0.52× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $518.6M | $359.1M | ||
| Q3 25 | $583.2M | $382.0M | ||
| Q2 25 | $630.3M | $695.6M | ||
| Q1 25 | $673.3M | $938.5M | ||
| Q4 24 | $725.3M | $912.8M | ||
| Q3 24 | $756.0M | $866.4M | ||
| Q2 24 | $802.3M | $757.0M | ||
| Q1 24 | $823.8M | $718.3M |
| Q4 25 | — | $568.7M | ||
| Q3 25 | — | $567.9M | ||
| Q2 25 | — | $566.8M | ||
| Q1 25 | — | $566.1M | ||
| Q4 24 | — | $565.3M | ||
| Q3 24 | — | $613.0K | ||
| Q2 24 | — | $563.2M | ||
| Q1 24 | — | $562.5M |
| Q4 25 | $527.2M | $1.1B | ||
| Q3 25 | $598.4M | $1.1B | ||
| Q2 25 | $655.4M | $1.2B | ||
| Q1 25 | $703.0M | $1.2B | ||
| Q4 24 | $747.0M | $1.1B | ||
| Q3 24 | $785.9M | $1.2B | ||
| Q2 24 | $813.7M | $1.0B | ||
| Q1 24 | $838.6M | $945.5M |
| Q4 25 | $583.0M | $2.2B | ||
| Q3 25 | $648.4M | $2.3B | ||
| Q2 25 | $692.4M | $2.1B | ||
| Q1 25 | $739.5M | $2.1B | ||
| Q4 24 | $792.3M | $2.0B | ||
| Q3 24 | $823.2M | $2.0B | ||
| Q2 24 | $845.6M | $1.9B | ||
| Q1 24 | $868.8M | $1.8B |
| Q4 25 | — | 0.52× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.49× | ||
| Q1 25 | — | 0.49× | ||
| Q4 24 | — | 0.52× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.55× | ||
| Q1 24 | — | 0.59× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-63.9M | $90.2M |
| Free Cash FlowOCF − Capex | $-65.2M | $81.4M |
| FCF MarginFCF / Revenue | -54350.8% | 20.0% |
| Capex IntensityCapex / Revenue | 1067.5% | 2.2% |
| Cash ConversionOCF / Net Profit | — | 1.67× |
| TTM Free Cash FlowTrailing 4 quarters | $-213.7M | $354.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-63.9M | $90.2M | ||
| Q3 25 | $-48.6M | $105.3M | ||
| Q2 25 | $-44.0M | $87.1M | ||
| Q1 25 | $-54.4M | $107.6M | ||
| Q4 24 | $-32.5M | $157.7M | ||
| Q3 24 | $-55.3M | $175.1M | ||
| Q2 24 | $-29.3M | $84.7M | ||
| Q1 24 | $-40.6M | $127.2M |
| Q4 25 | $-65.2M | $81.4M | ||
| Q3 25 | $-49.1M | $94.7M | ||
| Q2 25 | $-44.7M | $79.1M | ||
| Q1 25 | $-54.6M | $98.8M | ||
| Q4 24 | $-33.2M | $141.4M | ||
| Q3 24 | $-55.9M | $159.3M | ||
| Q2 24 | $-29.6M | $73.5M | ||
| Q1 24 | $-41.0M | $119.0M |
| Q4 25 | -54350.8% | 20.0% | ||
| Q3 25 | — | 24.7% | ||
| Q2 25 | -6127.8% | 20.9% | ||
| Q1 25 | -7861.4% | 26.5% | ||
| Q4 24 | -2828.3% | 36.1% | ||
| Q3 24 | -1751.2% | 42.0% | ||
| Q2 24 | -1185.0% | 18.7% | ||
| Q1 24 | -26270.5% | 32.2% |
| Q4 25 | 1067.5% | 2.2% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | 99.7% | 2.1% | ||
| Q1 25 | 38.1% | 2.3% | ||
| Q4 24 | 64.3% | 4.2% | ||
| Q3 24 | 17.1% | 4.2% | ||
| Q2 24 | 11.0% | 2.8% | ||
| Q1 24 | 220.5% | 2.2% |
| Q4 25 | — | 1.67× | ||
| Q3 25 | — | 3.79× | ||
| Q2 25 | — | 1.11× | ||
| Q1 25 | — | 1.47× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.34× | ||
| Q2 24 | — | 1.36× | ||
| Q1 24 | — | 0.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLDX
Segment breakdown not available.
LNTH
| Radiopharmaceutical Oncology | $240.2M | 59% |
| Definity | $85.3M | 21% |
| Strategic Partnerships And Other | $23.3M | 6% |
| Techne Lite | $21.0M | 5% |
| Licenseand Royalty Revenues | $17.4M | 4% |
| Other | $13.6M | 3% |
| Other Precision Diagnostics | $5.9M | 1% |
